PT - JOURNAL ARTICLE AU - Jason D. Gray AU - Michael Punsoni AU - Nora E. Tabori AU - Jay T. Melton AU - Victoria Fanslow AU - Mary J. Ward AU - Bojana Zupan AU - David Menzer AU - Jackson Rice AU - Carrie T. Drake AU - Russell D. Romeo AU - Wayne G. Brake AU - Annelyn Torres-Reveron AU - Teresa A. Milner TI - Methylphenidate Administration to Juvenile Rats Alters Brain Areas Involved in Cognition, Motivated Behaviors, Appetite, and Stress AID - 10.1523/JNEUROSCI.0109-07.2007 DP - 2007 Jul 04 TA - The Journal of Neuroscience PG - 7196--7207 VI - 27 IP - 27 4099 - http://www.jneurosci.org/content/27/27/7196.short 4100 - http://www.jneurosci.org/content/27/27/7196.full SO - J. Neurosci.2007 Jul 04; 27 AB - Thousands of children receive methylphenidate (MPH; Ritalin) for attention deficit/hyperactivity disorder (ADHD), yet the long-term neurochemical consequences of MPH treatment are unknown. To mimic clinical Ritalin treatment in children, male rats were injected with MPH (5 mg/kg) or vehicle twice daily from postnatal day 7 (PND7)–PND35. At the end of administration (PND35) or in adulthood (PND135), brain sections from littermate pairs were immunocytochemically labeled for neurotransmitters and cytological markers in 16 regions implicated in MPH effects and/or ADHD etiology. At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density. In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule). In medial striatum, TH-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH-exposed rats. At PND135, MPH-exposed rats exhibited decreased anxiety in the elevated plus-maze and a trend for decreased TH-ir in the mPFC. Neither PND35 nor PND135 rats showed major structural differences with MPH exposure. These findings suggest that developmental exposure to high therapeutic doses of MPH has short-term effects on select neurotransmitters in brain regions involved in motivated behaviors, cognition, appetite, and stress. Although the observed neuroanatomical changes largely resolve with time, chronic modulation of young brains with MPH may exert effects on brain neurochemistry that modify some behaviors even in adulthood.